Educell is a biopharmaceutical CDMO (contract development and manufacturing organization) specialized on cell and gene therapies (ATMPs - advanced therapy medicinal products) situated in EU. Educell has 25 years of experience on cell therapy and regenerative medicine, starting with cultivated chondrocytes, following with mesenchymal stromal/stem cells and now focusing on CAR-T therapy and some other immune therapies. With our high standard of quality, state of the art GMP certified laboratories, range of EU-compliant regulatory approvals and experienced personnel, we can offer a wide support to any institution developing their own ATMP.
Our expertise mainly encompasses the following topics:
- automated and closed system adherent cell cultivation (mesenchymal stromal/stem cells, chondrocytes, fibroblasts, keratinocytes, etc.)
- CAR-T manufacturing, upgrading from laboratory grade to GMP grade technology
- extracellular vesicle production in automated closed system
- Quality control, Quality assurance, etc.
- Releasing the batches of cells according to European legislation
- Help with clinical trial setup, finding interested clinicians in Slovenia, monitoring the Slovenian part of clinical trial.
Besides our CDMO services, we also have proprietary technologies with the potential to be registered as an ATMP in EU, thus we are seeking for investments into the technologies:
- Technology for cultivation of CD34 positive (hematopoietic stem) cells to be used as an alternative to normal bone marrow transplantation or 2 cord blood transplantations with better outcomes for the patients (Licenced in)
- MSC product that has been tested in real-world clinical setup for graft-versus-host disease (GvHD, on pediatric and adult patients), Crohns disease, COVID-19, Sacroiliitis, Osteoarthritis, etc.
- CAR-T technology against CD 19 based on 2nd generation CAR and 3rd generation of lentivirus (Licenced in)
